Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.
Publication
, Conference
Weant, M; Dunn-Pirio, A; Peters, K; Vlahovic, G; Randazzo, D; Herndon, J; Healy, P; Threatt, S; Sampson, J; Friedman, A; Friedman, H; Desjardins, A
Published in: Neuro-Oncology
ATCT-13
Duke Scholars
Published In
Neuro-Oncology
DOI
ISSN
1522-8517
Volume
17
Issue
Suppl. 5, abstr. ATCT-13
Location
San Antonio, TX
Publisher
Oxford University Press (OUP)
Conference Name
20th Annual Scientific Meeting and Educations Day of the Society for Neuro-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J., … Desjardins, A. (n.d.). Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. In Neuro-Oncology (Vol. 17). San Antonio, TX: Oxford University Press (OUP). https://doi.org/10.1093/neuonc/nov206.13
Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro-Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, et al. Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. In: Neuro-Oncology. Oxford University Press (OUP);
Weant, Mallika, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” Neuro-Oncology, vol. 17, no. Suppl. 5, abstr. ATCT-13, Oxford University Press (OUP). Manual, doi:10.1093/neuonc/nov206.13.
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Neuro-Oncology. Oxford University Press (OUP);
Published In
Neuro-Oncology
DOI
ISSN
1522-8517
Volume
17
Issue
Suppl. 5, abstr. ATCT-13
Location
San Antonio, TX
Publisher
Oxford University Press (OUP)
Conference Name
20th Annual Scientific Meeting and Educations Day of the Society for Neuro-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences